Evidence map›Paper›PMID 40954096›Full record

ArticleACS chemical neuroscience2025

Potential Region-Specific Neuroprotective Effects of Kynurenine Administration in Healthy Rodents Using High-Resolution Mass Spectrometry.

Sandy Abujrais, Anne Simeit, Mara Link, Fleur Kalberg, Leandrie Pienaar, Radhini Veerappan, Aletta Me Millen, Sooraj Baijnath, Jonas Bergquist

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS chemical neuroscience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Sandy AbujraisAnalytical Chemistry and Neurochemistry, Department of Chemistry-BMC, Uppsala University, Uppsala 75124, Sweden.ORCID 0000-0002-1731-3711
Anne SimeitAnalytical Chemistry and Neurochemistry, Department of Chemistry-BMC, Uppsala University, Uppsala 75124, Sweden.
Mara LinkAnalytical Chemistry and Neurochemistry, Department of Chemistry-BMC, Uppsala University, Uppsala 75124, Sweden.
Fleur KalbergAnalytical Chemistry and Neurochemistry, Department of Chemistry-BMC, Uppsala University, Uppsala 75124, Sweden.
Leandrie PienaarWits Integrated Molecular Physiology Research Initiative, Wits Health Consortium (PTY) Ltd., School of Physiology, Faculty of Health Sciences, University of The Witwatersrand, Johannesburg 2050, South Africa.
Radhini VeerappanWits Integrated Molecular Physiology Research Initiative, Wits Health Consortium (PTY) Ltd., School of Physiology, Faculty of Health Sciences, University of The Witwatersrand, Johannesburg 2050, South Africa.
Aletta Me MillenWits Integrated Molecular Physiology Research Initiative, Wits Health Consortium (PTY) Ltd., School of Physiology, Faculty of Health Sciences, University of The Witwatersrand, Johannesburg 2050, South Africa.
Sooraj BaijnathWits Integrated Molecular Physiology Research Initiative, Wits Health Consortium (PTY) Ltd., School of Physiology, Faculty of Health Sciences, University of The Witwatersrand, Johannesburg 2050, South Africa.
Jonas BergquistAnalytical Chemistry and Neurochemistry, Department of Chemistry-BMC, Uppsala University, Uppsala 75124, Sweden.ORCID 0000-0002-4597-041X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The tryptophan (TRP) metabolic pathway produces kynurenine (KYN) and serotonin (5-HT). These are important molecules in the central nervous system, as KYN plays a crucial role in neuroprotection, while 5-HT impacts mood and sleep patterns. The production of KYN is increased in response to inflammatory cytokines and cortisol release, which activates indoleamine 2,3-dioxygenase (IDO) and tryptophan 2,3-dioxygenase (TDO), respectively. These enzymes are responsible for converting TRP and KYN into neuroactive molecules including kynurenic acid (KA), quinolinic acid (QA), and 3-hydroxykynurenine (3HK). These metabolites play an important role in neuroprotection and have been linked to the development of several neurological disorders. Therefore, the aim of this study was to investigate the effect of exogenous KYN administration on the activity of the KYN pathway by measuring the brain tissue concentration of these metabolites and the mRNA expression of inflammatory markers, neurotrophic factors, IDO, and TDO. In the acute study, Sprague-Dawley rats (

Indexed as

BrainKynurenineNeuroprotective AgentsAnimalsIndoleamine-Pyrrole 2,3,-DioxygenaseKynurenic AcidMaleMass SpectrometryQuinolinic AcidRatsRats, Sprague-DawleyRNA, MessengerTryptophanTryptophan OxygenaseIndoleamine-Pyrrole 2,3,-DioxygenaseKynurenic AcidKynurenineNeuroprotective AgentsQuinolinic AcidRNA, MessengerTryptophanTryptophan Oxygenaseinflammationkynurenic acidkynureninekynurenine administrationneurological disordersneuroprotectiontryptophan metabolism

Identifiers

PMID40954096
PMCPMC12498425

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.